Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group.

Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TL; Dominantly Inherited Alzheimer Network.

PLoS One. 2016 Mar 24;11(3):e0152082. doi: 10.1371/journal.pone.0152082. eCollection 2016. Erratum in: PLoS One. 2016 Sep 20;11(9):e0163669.

2.

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.

Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Schöll M, Chiotis K, Thordardottir S, Graff C, Wall A, Långström B, Nordberg A.

Brain. 2016 Mar;139(Pt 3):922-36. doi: 10.1093/brain/awv404. Epub 2016 Jan 26.

3.

Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.

Förster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Förstl H, Kurz A, Grimmer T, Drzezga A.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1927-36. doi: 10.1007/s00259-012-2230-9. Epub 2012 Aug 28.

PMID:
22926714
4.

Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET.

Chen YJ, Rosario BL, Mowrey W, Laymon CM, Lu X, Lopez OL, Klunk WE, Lopresti BJ, Mathis CA, Price JC.

J Nucl Med. 2015 Aug;56(8):1199-205. doi: 10.2967/jnumed.114.152405. Epub 2015 Jun 4.

5.

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA.

J Cereb Blood Flow Metab. 2005 Nov;25(11):1528-47.

PMID:
15944649
6.

Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.

Brendel M, Delker A, Rötzer C, Böning G, Carlsen J, Cyran C, Mille E, Gildehaus FJ, Cumming P, Baumann K, Steiner H, Haass C, Herms J, Bartenstein P, Rominger A.

Neuroimage. 2014 Jan 1;84:843-53. doi: 10.1016/j.neuroimage.2013.09.017. Epub 2013 Sep 20.

PMID:
24055703
7.

Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue.

Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A.

Brain. 2013 Jul;136(Pt 7):2217-27. doi: 10.1093/brain/awt142. Epub 2013 Jun 11.

PMID:
23757761
8.

Partial volume correction in quantitative amyloid imaging.

Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, Bateman RJ, Cairns NJ, Aldea P, Cash L, Christensen JJ, Friedrichsen K, Hornbeck RC, Farrar AM, Owen CJ, Mayeux R, Brickman AM, Klunk W, Price JC, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Schofield PR, Buckles V, Morris JC, Benzinger TLS; Dominantly Inherited Alzheimer Network.

Neuroimage. 2015 Feb 15;107:55-64. doi: 10.1016/j.neuroimage.2014.11.058. Epub 2014 Dec 5.

9.

Optimizing regions-of-interest composites for capturing treatment effects on brain amyloid in clinical trials.

Tryputsen V, DiBernardo A, Samtani M, Novak GP, Narayan VA, Raghavan N; Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;43(3):809-21. doi: 10.3233/JAD-131979.

PMID:
25114074
10.

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.

Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, Pontecorvo M, Baker SL, Jagust WJ; Alzheimer’s Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1398-407. doi: 10.1007/s00259-014-2753-3. Epub 2014 Mar 20.

11.

Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.

Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, Reiman EM, Jagust WJ.

J Nucl Med. 2015 Apr;56(4):567-74. doi: 10.2967/jnumed.114.148981. Epub 2015 Mar 5.

12.

Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.

Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, McDade E, Aizenstein HJ, Klunk WE, Mathis CA.

Neuroimage Clin. 2015 Oct 14;9:592-8. doi: 10.1016/j.nicl.2015.10.007. eCollection 2015.

13.

Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET.

Rosario BL, Weissfeld LA, Laymon CM, Mathis CA, Klunk WE, Berginc MD, James JA, Hoge JA, Price JC.

Neuroimage. 2011 Apr 1;55(3):933-41. doi: 10.1016/j.neuroimage.2010.12.070. Epub 2010 Dec 31.

14.

The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease.

Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, Hutton BF.

Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1104-19. doi: 10.1007/s00259-011-1745-9. Epub 2011 Feb 19.

PMID:
21336694
15.

Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers.

Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodríguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN.

Brain. 2011 Jan;134(Pt 1):293-300. doi: 10.1093/brain/awq310. Epub 2010 Nov 16.

PMID:
21084313
16.

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC.

Brain. 2008 Mar;131(Pt 3):665-80. doi: 10.1093/brain/awm336. Epub 2008 Feb 7.

17.

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST.

Brain. 2008 Jun;131(Pt 6):1630-45. doi: 10.1093/brain/awn016. Epub 2008 Mar 12.

18.

Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.

Rabinovici GD, Furst AJ, Alkalay A, Racine CA, O'Neil JP, Janabi M, Baker SL, Agarwal N, Bonasera SJ, Mormino EC, Weiner MW, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ.

Brain. 2010 Feb;133(Pt 2):512-28. doi: 10.1093/brain/awp326. Epub 2010 Jan 15.

19.

Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC.

J Nucl Med. 2005 Dec;46(12):1959-72.

20.

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.

Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, La Joie R, Arthur-Bentil SK, Vogel JW, Marks SM, Lehmann M, Rosen HJ, Reed B, Olichney J, Boxer AL, Miller BL, Borys E, Jin LW, Huang EJ, Grinberg LT, DeCarli C, Seeley WW, Jagust W.

Brain. 2015 Jul;138(Pt 7):2020-33. doi: 10.1093/brain/awv112. Epub 2015 May 6.

Supplemental Content

Support Center